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OBJECTIVE—Recent advances in type 2 diabetes genetics have
culminated in the discovery and conﬁrmation of multiple risk
variants. Two important and largely unanswered questions are
whether this information can be used to identify individuals most
susceptible to the adverse consequences of sedentary behavior
and to predict their response to lifestyle intervention; such
evidence would be mechanistically informative and provide a
rationale for targeting genetically susceptible subgroups of the
population.
RESEARCH DESIGN AND METHODS—Gene  physical
activity interactions were assessed for 17 polymorphisms in a
prospective population-based cohort of initially nondiabetic mid-
dle-aged adults. Outcomes were 1) impaired glucose regulation
(IGR) versus normal glucose regulation determined with either
fasting or 2-h plasma glucose concentrations (n  16,003), 2)
glucose intolerance (in mmol/l, n  8,860), or 3) incident type 2
diabetes (n  2,063 events).
RESULTS—Tests of gene  physical activity interactions on
IGR risk for 3 of the 17 polymorphisms were nominally statisti-
cally signiﬁcant: CDKN2A/B rs10811661 (Pinteraction  0.015),
HNF1B rs4430796 (Pinteraction  0.026), and PPARG rs1801282
(Pinteraction  0.04). Consistent interactions were observed for
the CDKN2A/B (Pinteraction  0.013) and HNF1B (Pinteraction 
0.0009) variants on 2-h glucose concentrations. Where type 2
diabetes was the outcome, only one statistically signiﬁcant
interaction effect was observed, and this was for the HNF1B
rs4430796 variant (Pinteraction  0.0004). The interaction effects
for HNF1B on IGR risk and incident diabetes remained signiﬁ-
cant after correction for multiple testing (Pinteraction  0.015 and
0.0068, respectively).
CONCLUSIONS—Our observations suggest that the genetic
predisposition to hyperglycemia is partially dependent on a
person’s lifestyle. Diabetes 58:1411–1418, 2009
R
ecent advances in high-throughput genotyping
methods have facilitated the discovery and con-
ﬁrmation (1–7) of multiple common genetic risk
factors for type 2 diabetes. The notion of using
genetic information for disease prevention is predicated
on the assumption that genetic risk can be offset with drug
or lifestyle intervention. Thus, studies that explore this
possibility are integral to the process of translating the
results of genetic association studies into preventive prac-
tice. Furthermore, because interaction effects modify the
extent to which genetic risk is conveyed, with the risk
varying in magnitude across the spectrum of environmen-
tal exposure, information on gene  environment interac-
tions may help improve the sensitivity and speciﬁcity of
genetic prediction models (8).
In a recent report from the Diabetes Prevention Pro-
gram, 10 of the previously associated type 2 diabetes risk
polymorphisms were assessed in the context of a clinical
trial of drug or lifestyle intervention for diabetes risk
reduction (9). In that study, a single nucleotide polymor-
phism (SNP) at the cyclin-dependent kinase inhibitor 2A/B
(CDKN2A/B) locus (rs10811661) was shown to modify the
effects of lifestyle intervention on diabetes risk reduction,
such that the lifestyle intervention slowed the progression
to type 2 diabetes to a greater extent in those carrying the
previously reported high-risk genotype at rs10811661 com-
pared with those with the lower-risk genotypes.
In the current study, we aimed to determine whether the
effects of 17 previously associated type 2 diabetes gene
variants on the risk of impaired glucose regulation (IGR)
or incident type 2 diabetes are modiﬁed by physical
activity. The study was undertaken in an ethnically homo-
geneous prospective population-based cohort study of
16,000 initially nondiabetic middle-aged adults from
Sweden.
RESEARCH DESIGN AND METHODS
A preventive case-ﬁnding program called the Malmo ¨ Preventive Project was
started in 1974 at the Department of Preventive Medicine, University Hospital,
Malmo ¨, Sweden. The aim was to screen large strata of the adult population in
the southern Swedish city of Malmo ¨ to ﬁnd individuals at high risk of
developing chronic diseases who might beneﬁt from preventive interventions.
Participants were invited to participate in a general health screening that
included a physical examination, a self-administered questionnaire on lifestyle
habits, and fasting and postchallenge blood sampling for laboratory tests.
Between 1974 and 1992, a total of 22,444 male and 10,902 female subjects
attended the screening program, with an overall attendance rate of 71%. All
participants gave written informed consent to take part in the study, which
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Follow-up for incident type 2 diabetes. A detailed description of the case
ascertainment and other follow-up procedures is given elsewhere (10,11).
Brieﬂy, all known prevalent cases of type 2 diabetes were excluded from the
cohort. Incident diabetes (n  2,063 events) was ascertained using informa-
tion collected from hospital records detailing a clinical diagnosis of type 2
diabetes or a fasting plasma glucose value 7.0 mmol/l at one of the Malmo ¨
Preventive Project follow-up examinations.
Clinical measurements. The clinical examination included measurements of
height (m) and weight (kg) as previously described (11). Blood samples were
drawn at 0, 40, and 120 min of an oral glucose tolerance test for measurements
of blood glucose using a hexokinase method, the details of which have
previously been described in detail (12). BMI was calculated as the weight in
kilograms divided by height in meters squared (kg/m
2). IGR was deﬁned as an
elevated 2-h glucose concentration of 7.8–11.0 mmol/l (or an elevated fasting
value of 5.6–6.9 mmol/l if the 2-h value was unavailable), whereas normal
glucose regulation (NGR) was deﬁned as a 2-h glucose concentration 7.8
mmol/l (or a fasting value 5.6 mmol/l if the 2-h value was unavailable).
Measurement of physical activity. Physical activity was assessed using a
self-administered computer-based questionnaire. The current study spanned a
number of years, and during that time the questions used to assess physical
activity were changed. The different questions used throughout the survey are
shown below. Therefore, we constructed a variable where individuals were
classiﬁed as “physically active” if they had answered “yes” when responding to
one of the following questions used to assess physical activity throughout the
duration of the survey: 1) Do you walk or cycle to and from work? 2)D oy o u
walk or cycle for recreation during weekdays? 3) Do you walk or cycle for
recreation during weekend days? 4) Do you undertake at least 3 h per week
of structured physical exercise? 5) Do you walk to work or do yard work? or
6) Do you perform light structured physical exercise each week? Conversely,
those who answered “no” to these questions were classiﬁed as “physically
inactive.” In this report, the physical activity variable was associated with
glucose concentrations and diabetes incidence (see the RESULTS section) in a
manner consistent with prior studies using objective assessment methods
(13), indicating that the questionnaire used here correctly classiﬁes individu-
als into physically active and inactive subgroups.
Genotyping. All polymorphisms have previously been examined for associ-
ation with incident type 2 diabetes in this cohort (10,14,15). Data on the
association between MTNR1B (rs10830963) and fasting glucose also have
previously been reported (15). A Plasmid Maxi Kit (Qiagen) was used to
extract DNA from white blood cells. For the rs7903146, rs1801282, rs5219,
rs7754840, and rs10811661 variants, genotyping was performed using the
matrix-assisted laser desorption–ionization time-of-ﬂight mass spectrometry
method on a MassARRAY platform (Sequenom). For rs4430796, rs4402960,
rs10010131, rs1111875, rs864745, rs12779790, rs7961581, rs7578597, rs4607103,
rs10923931, and rs10830963, genotyping was performed using an allelic
discrimination assay-by-design approach on an ABI 7900 (Applied Biosys-
tems). The rs13266634 variant was genotyped using an allele-speciﬁc assay
(KASPar; KBioscience). The genotyping success rate and accuracy (11% of
samples were regenotyped using Sequenom) exceeded 95 and 98.7%, respec-
tively. As previously described, the concordance rates for the vast majority of
SNPs exceeded 99% (10,15). All variants fulﬁlled Hardy-Weinberg expectations
(P  0.001).
Statistical analysis. Statistical analyses were conducted using SAS software
(version 9.1; SAS Institute, Cary, NC). Hardy-Weinberg equilibrium was
assessed using Haploview version 4.0 (http://www.broad.mit.edu/mpg/
haploview). Statistical power was calculated with Quanto (version 1.2.3) (16)
using parameters described in the legend of Table 3. Logistic regression
adjusted for age, sex, and BMI was used to determine the strength of the
relationship between physical activity and IGR. Differences between means
were calculated using independent sample, two-sided Student’s t tests to
establish whether age, BMI, and glucose levels differed between active and
inactive individuals. A likelihood ratio test with 1 degree of freedom was used
to calculate the difference for categorical traits. For models where glucose
tolerance was expressed as a binary variable (i.e., NGR vs. IGR), logistic
regression was used, including interaction terms for genotype  physical
activity. Generalized linear models were used to test associations and
interactions (also incorporating an interaction term for genotype  physical
activity) for each of the gene variants and with 2-h glucose concentrations as
the dependent variable. Cox proportional hazards regression models were
used to test main genetic effects (genes and physical activity separately) and
gene  physical activity interactions on type 2 diabetes incidence. A time-
dependent interaction term was ﬁtted to the model to ensure that the
proportionalityassumptionofCoxmodelswasfulﬁlled,whichitwas(Pinteraction
 0.05). All regression models were adjusted for age, sex, and BMI and
assumed an additive mode of genetic inheritance. Adjustments for multiple
statistical comparisons across the 17 polymorphisms were made for each of
the three dependent variables using the Holm procedure (17). This procedure
requires that the probability statistics for each hypothesis test is placed in a
rank-ordered list, with the highest P value appearing ﬁrst. The total number of
P values within this list represents the denominator. The least signiﬁcant
nominal P value is divided by 1, the second least signiﬁcant by 2, and so on
until all P values within the list have been corrected. This correction method
was applied to each dependent variable separately.
RESULTS
Participant characteristics for 16,003 initially nondiabetic
middle-aged whites are shown in Table 1. To indirectly
quantify the validity of the physical activity assessment
instrument, we tested the association between physical
activity and IGR or diabetes risk after adjustment for age,
sex, and BMI. In these models, physical inactivity con-
veyed a 1.15-fold increased risk (95% CI 1.05–1.26, P 
0.002) of IGR and a 1.41-fold increased risk (1.29–1.57, P 
0.0001) of type 2 diabetes.
The following section describes the results for the
models focusing on main genetic effects and gene 
physical activity interactions. Unless otherwise stated, all
P values are unadjusted for multiple comparisons.
Genetic association models (main effects). The asso-
ciations between each of the polymorphisms with IGR risk
and 2-h glucose concentrations are shown in Table 2,
ranked by the P value for the test of gene  physical
activity interaction. SLC30A8 (rs13266634), TCF7L2
(rs7903146), CDKAL1 (rs7754840), NOTCH2 (rs10923931),
KCNJ11 (rs5219), IGFBP2 (rs4402960), JAZF1 (rs864745),
HHEX (rs1111875), MTNR1B (rs10830963), and TSPAN8
(rs7961581) all showed evidence for association with IGR
risk and/or 2-h glucose concentrations in directions con-
sistent with previous reports. No statistical association
was observed between the CDKN2A/B rs10811661 variant
and 2-h glucose (0.02 mmol/l per copy of the major
allele, P  0.43) or the risk of having IGR (vs. NGR; odds
ratio [OR] 1.08 per copy of the major allele, 95% CI
0.99–1.15, P  0.08). Similarly, no statistical association
was observed for the HNF1B rs4430796 variant and 2-h
glucose (0.02 mmol/l per copy of the minor allele, P 
0.65) or IGR risk (OR 1.02 per copy of the minor allele, 95%
CI 0.97–1.08, P  0.36). The associations between each of
TABLE 1
Participant characteristics stratiﬁed by level of physical activity
(n  16,003)
Variable
Physically
inactive
Physically
active P
n 3,455 12,548 —
Sex (M/F) 2,287/1,168 8,115/4,433 0.097
Baseline age (years) 44.7  7.3 45.7  6.8 0.0001
Baseline BMI (kg/m
2) 24.6  3.7 24.2  3.1 0.0001
Baseline fasting glucose
(mmol/l) 4.87  0.48 4.81  0.49 0.0001
Baseline 2-h glucose
(mmol/l)* 5.67  1.54 5.64  1.44 0.480
Baseline glucose
regulation (NGR/IGR) 2,585/870 9,601/2,947 0.038
Developed diabetes
(no/yes) 2,958/497 10,982/1,566 0.003
Data are N or means  SD. Differences between means were
calculated using a two-sided, independent sample Student’s t test.
Differences between proportions were tested using a likelihood ratio
test with 1 degree of freedom. *Available in subsamples of n  1,647
(physically inactive) and n  7,217 (physically active).
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described in detail (10,15).
Gene  physical activity interaction models. Statisti-
cal power calculations are shown in Table 3 for all
variants. As shown in Table 2, no statistical evidence of
interaction emerged for the majority of the polymorphisms
tested. The remaining section focuses on the variants for
which the uncorrected interaction terms were statistically
signiﬁcant (Pinteraction  0.05) for at least one of the three
outcomes of interest in this report.
HNF1B (rs4430796). The gene  physical activity inter-
action terms for HNF1B (rs4430796) on IGR risk and on
2-h glucose concentrations were both statistically signiﬁ-
cant (Pinteraction  0.026 and 0.0009, respectively), and the
latter remained signiﬁcant after correction for multiple
hypothesis testing (Pinteraction  0.015). Although not sta-
tistically signiﬁcant, the minor A allele at HNF1B
rs4430796 tended to be associated with lower risk of IGR
(OR 0.92 per allele, 95% CI 0.82–1.03, P  0.13) in physi-
cally inactive individuals (n  3,335) and with increased
risk (1.06, 1.00–1.12, P  0.066) in physically active
individuals (n  12,015). In a concordant manner, the
minor A allele was associated with lower 2-h glucose
levels ( 0.13 mmol/l per allele, P  0.005) in
physically inactive individuals (n  1,619), with a contrast-
ing effect (0.04, P  0.056) in physically active individuals
(n  6,981) (Fig. 1). The Cox proportional hazards regres-
sion model testing the gene  baseline physical activity
interaction term on type 2 diabetes as the outcome yielded
an uncorrected P value of 0.0004 (corrected Pinteraction 
0.0068). The nature of the interaction reﬂected those
observed in the glucose regulation models, where the
minor allele was associated with decreased risk of diabe-
tes in sedentary individuals (hazard rate ratio [HRR] 
0.85; 95% CI 0.74–0.96; P  0.011), with a contrasting effect
in physically active individuals (HRR  1.10; 95% CI
1.03–1.18; P  0.007). To illustrate this interaction, cumu-
lative incidence curves were plotted stratiﬁed by genotype
and level of physical activity (see Fig. 2).
CDKN2A/B (rs10811661). The interaction terms for the
CDKN2A/B rs10811661 polymorphism and physical activ-
ity, with IGR risk or 2-h glucose concentrations as out-
comes, were both nominally statistically signiﬁcant
(Pinteraction  0.015 and 0.013, respectively). Though not
statistically signiﬁcant, the minor allele at rs10811661
tended to be associated with higher risk of IGR (OR 1.10
per allele, 95% CI 0.95–1.28, P  0.20) in physically inactive
individuals (n  3,468), but it was protective of IGR risk
(0.89, 0.82–0.97, P  0.0075) in active individuals (n 
12,525). Similarly, in physically inactive individuals (n 
1,618), the rs10811661 minor allele tended to be associated
with elevated 2-h glucose concentrations (0.12 mmol/l
per allele, P  0.064), whereas in physically active individ-
uals (n  6,680), a contrasting effect was observed (0.06,
P  0.070), although neither was statistically signiﬁcant.
No statistical evidence of interaction was observed where
type 2 diabetes was the outcome (Pinteraction  0.57).
PPARG (rs1801282). The interaction between the
PPARG rs1801282 polymorphism and physical activity on
TABLE 3
Statistical power calculations to detect gene  physical activity interactions on IGR or type 2 diabetes risk
Nearest
gene Variant Alleles MAF Power for IGR (%)
Power for type 2
diabetes (%)
CDKN2A/B rs10811661 T/C 0.16 0.49–0.99 0.30–0.94
HNF1B rs4430796 G/A 0.46 0.84–0.99 0.63–0.99
PPARG rs1801282 C/G 0.14 0.44–0.99 0.29–0.92
SLC30A8 rs13266634 C/T 0.32 0.78–0.99 0.58–0.99
WFS1 rs10010131 G/A 0.43 0.86–0.99 0.63–0.99
TCF7L2 rs7903146 C/T 0.26 0.72–0.99 0.53–0.99
ADAMTS9 rs4607103 C/T 0.23 0.67–0.99 0.45–0.99
CDKAL1 rs7754840 G/C 0.31 0.78–0.99 0.57–0.99
CAMK1D rs12779790 A/G 0.19 0.58–0.99 0.38–0.98
NOTCH2 rs10923931 G/T 0.10 0.31–0.95 0.20–0.84
KCNJ11 rs5219 G/A 0.38 0.82–0.99 0.61–0.99
THADA rs7578597 T/C 0.10 0.30–0.95 0.16–0.78
IGFBP2 rs4402960 G/T 0.30 0.77–0.99 0.56–0.99
JAZF1 rs864745 A/G 0.49 0.85–0.99 0.64–0.99
HHEX rs1111875 G/A 0.41 0.83–0.99 0.62–0.99
MTNR1B rs10830963 C/G 0.28 0.75–0.99 0.53–0.99
TSPAN8 rs7961581 T/C 0.26 0.71–0.99 0.51–0.99
Environmental risk (OR) for IGR  1.15 and for type 2 diabetes  1.41 (as shown in the RESULTS section). Genetic risk (OR) is taken from
Table 2 and Lyssenko et al. (10,15). Background population disease risk was set at 5%. Detectable interaction effect sizes (RGE) are 1.25–1.50
per copy of the minor allele. Two-sided Pinteraction  0.00294 (i.e., Pinteraction  0.05 corrected for 17 tests). Power is for log-additive genetic
models. Alleles are coded as major/minor and are from the National Center for Biotechnology Information Build 36.3 (HapMap-CEU). MAF,
minor allele frequency.
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0.04). In inactive individuals, the minor allele appeared to
be protective of IGR (OR 0.88 per allele, 95% CI 0.75–1.02,
P  0.097), whereas this effect was reversed in active
individuals (1.05, 0.97–1.15, P  0.22), albeit neither strat-
iﬁed effect was statistically signiﬁcant. No evidence of sta-
tistical interaction was observed for 2-h glucose
concentrations (Pinteraction  0.78) or incident diabetes
(Pinteraction  0.67).
Tests of gene  BMI interaction on IGR risk. It is
possible that the interactions reported above might be
driven by interactions between the gene variants and BMI
because both physical activity and BMI are related (13).
Therefore, we tested age- and sex-adjusted BMI interac-
tion terms for each SNP with the dependent variable being
IGR vs. NGR. In these models, only one term, for
ADAMTS9 rs4607103, was nominally statistically signiﬁ-
cant (Pinteraction  0.024). The BMI interaction terms for
the CDKN2A/B rs10811661 (Pinteraction  0.973), HNF1B
rs4430796 (Pinteraction  0.763), and PPARG rs1801282
(Pinteraction  0.724) variants did not approach statistical
signiﬁcance. The inclusion or exclusion of BMI as a
covariate in the SNP  physical activity interaction mod-
els made no material difference to the interaction results,
and no novel interaction effects emerged.
DISCUSSION
A growing number of gene variants have been convinc-
ingly shown to inﬂuence type 2 diabetes risk (1–3,18,19).
In the current study, the risk of glucose intolerance and
type 2 diabetes conveyed by one of these variants (HNF1B
rs4430796) appeared to be offset in people reporting
physically active lifestyles. These putative interactions
were observed in 16,000 people, of whom 2,000 devel-
oped type 2 diabetes during a median follow-up period of
24.5 years. Consistent interaction effects emerged in the
subgroup of nearly 9,000 individuals in whom 2-h glucose
concentrations in response to an oral glucose tolerance
test had been recorded. The uncorrected interaction effect
for a second variant at CDKN2A/B (rs10811661) was
nominally statistically signiﬁcant when baseline IGR or 2-h
glucose was the outcome. The nature of these effects is
consistent with those reported in a recent clinical trial of
intensive lifestyle intervention (9). However, when type 2
diabetes was the outcome, the gene  physical activity
interaction term was not statistically signiﬁcant in this
cohort. A borderline uncorrected statistical interaction on
IGR risk for a third variant at the PPARG gene (rs1801282)
was also observed, but this was not apparent within the
subcohort in which 2-h glucose concentrations were avail-
able, nor was an interaction evident when type 2 diabetes
was the outcome. The absence of a statistical interaction
in the cohort with 2-h glucose concentrations may be a
consequence of lower statistical power owing to the
smaller sample size, but inadequate power is unlikely to
explain the lack of effect where diabetes was the outcome.
For this locus, numerous prior reports of gene-lifestyle
interaction exist, although most have focused on gene-
nutrient interaction effects (20).
HNF1B (also known as TCF2) encodes a homeobox
transcription factor that controls cell proliferation and
differentiation in the kidney, pancreas, liver, and genital
tract tissues. Rare monogenic forms of maturity-onset
diabetes of the young (MODY5) are caused by HNF1B
mutations (21). In the initial reports of association be-
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FIG. 2. Type 2 diabetes cumulative incidence plots stratiﬁed by level of
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diabetes (22), the major G allele was associated with
decreased risk, as observed in physically active individuals
in the current study. However, any beneﬁcial effect of this
allele is essentially lost, and possibly reversed, in the
physically inactive individuals studied here. From Fig. 2, it
is apparent that the initially strong inverse association
between physical activity and diabetes incidence dimin-
ishes in magnitude with each additional copy of the minor
HNF1B allele. This result suggests that the protective
effects of physical activity on diabetes risk may be atten-
uated in carriers of the rs4430796 minor allele. Interest-
ingly, the same variant was associated in the opposite
direction with prostate cancer risk in the initial report
(22). Thus, it would be important to determine whether
gene  physical activity interactions are also relevant for
that disease and, if so, how lifestyle intervention inﬂu-
ences prostate cancer risk in carriers of the different
rs4430796 genotypes. No prior studies to our knowledge
have reported evidence of gene  physical activity inter-
actions at the HNF1B rs4430796 locus. Thus, unlike the
interactions for CDKN2A/B and PPARG, the prior probability
that the HNF1B interaction tests would be statistically sig-
niﬁcant was low; therefore, that these tests remained statis-
tically signiﬁcant after correction for multiple testing
strengthens the credibility of our observations.
The CDKN2A and CDKN2B genes localize to neighbor-
ing genomic regions. Both genes function as tumor supres-
sors via inhibition of cyclin-dependent kinases (23). The
CDKN2A/B genes are highly expressed in adipocytes and
pancreatic islets (4). The rs10811661 polymorphism, which
maps to a region between CDKN2A and CDKN2B, was
initially identiﬁed through genome-wide association stud-
ies of type 2 diabetes risk (1,2,18,19). Several (7,24–27),
but not all (28), subsequent studies found strong support
for an association with type 2 diabetes at this locus in a
range of ethnic groups. Consistent with our observations
in physically active individuals, the major T allele was
associated with increased risk in prior reports
(1,7,18,19,24–27). In one of the follow-up studies (7), the
authors reported moderately elevated 2-h glucose concen-
trations in nondiabetic T allele carriers. The validity of the
CDKN2A/B  physical activity interaction observed here
is supportive of a recent report from the Diabetes Preven-
tion Program (9), where the effect of the rs10811661
polymorphism on diabetes risk was abolished with inten-
sive lifestyle intervention. These data tend to suggest that
whereas they are protected from IGR or type 2 diabetes
when physically active, carriers of the minor allele at
rs10811661 are, relative to the major allele homozygotes,
at increased risk of these conditions when leading seden-
tary lifestyles.
The third polymorphism for which we observed weak
evidence of statistical interaction is PPARG rs1801282
(encoding a proline-to-alanine amino acid substitution at
codon 12). Although the data supporting gene  physical
activity interactions at the rs1801282 locus are tenuous,
the variant is a strong biological and statistical candidate
for gene-nutrient (i.e., fatty acids) interactions (20,29).
Hence, because dietary patterns and physical activity tend
to coalesce within free-living populations, our observation
of gene  physical activity interaction may be attributable
to dietary correlates of physical activity, rather than direct
biological interactions between PPARG and physical ac-
tivity—unfortunately, measures of dietary fat intake were
unavailable for these analyses. Nonetheless, it is important
to stress that the statistical evidence of the interaction
between PPARG rs1801282 and physical activity is of
nominal statistical signiﬁcance for IGR risk, and no inter-
action was observed on 2-h glucose concentrations or type
2 diabetes incidence. Therefore, the tentative interaction
for IGR risk may be attributable to chance.
This is the ﬁrst study to our knowledge to assess
gene-lifestyle interactions across a wide range of previ-
ously associated type 2 diabetes gene variants. It is also
the largest study of gene-lifestyle interaction on pre-
diabetic and diabetic traits to date and, hence, one of the
most well powered to test related hypotheses. To illustrate
this point, we calculated the power to detect statistically
signiﬁcant interactions for the loci of interest (Table 3).
Although it is very difﬁcult at this stage to estimate the
magnitude of interaction effects because so few well-
designed interaction studies exist from which to garner
this information, a conservative estimate is that they might
range from 1.25 to 1.50. As Table 3 shows for IGR and type
2 diabetes as outcomes, our study was well powered to
detect interactions of 1.50 per allele.
A limitation of this report, as with all existing large-scale
epidemiological investigations, is that physical activity
was assessed using questionnaires, which are prone to
error and bias. This will have detrimentally affected power
to detect interactions owing to a degree of misclassiﬁca-
tion of the environmental exposure. However, our mea-
sure of physical activity is inversely correlated with IGR
and type 2 diabetes risk in this cohort, which is consistent
with the direction of association reported in clinical trials
involving exercise as part of a program of intensive
lifestyle intervention (30,31) or epidemiological studies
where physical activity was objectively assessed (13),
instilling conﬁdence that the questionnaire correctly clas-
siﬁed the behavior of physical activity. Moreover, we
purposefully studied people free from diabetes at baseline
to minimize the extent to which changes in behavior and
cognition attributable to disease labeling and treatment
might bias the reporting of physical activity levels by study
participants. In the future, large studies may emerge where
physical activity has been objectively assessed. In this
event, it may be possible to model genetic interaction
terms where the different components of physical activity
are examined. This is an important objective in furthering
our understanding of how behavioral and genetic predis-
positions interact to inﬂuence disease risk, but this is
beyond the scope of the current study.
Given that our study is likely to be adequately powered
to detect realistic interaction effects, the absence of sta-
tistical interactions for the majority of variants examined
here supports the idea that the most strongly associated
SNPs derived from existing type 2 diabetes genome-wide
association studies do not, by and large, exert their effects
through interactions with physical activity. To some ex-
tent, this is unsurprising because existing genome-wide
association studies are insensitive to detecting variants
with heterogeneous effects, owing to the strict signiﬁcance
thresholds used to determine genome-wide statistical sig-
niﬁcance. Thus, the most strongly associated variants in
genome-wide association studies are likely to be those
with the least heterogeneous effects, which by deﬁnition
are likely to exclude many variants that exert their effects
through interactions with environmental (or other genetic)
exposures.
In summary, in this study we examined putative gene 
physical activity interactions for 17 conﬁrmed type 2
GENE-LIFESTYLE INTERACTION AND HYPERGLYCEMIA
1416 DIABETES, VOL. 58, JUNE 2009diabetes risk variants on measures of glucose intolerance
and incident type 2 diabetes. Our ﬁndings, in combination
with other previously published observations (9), suggest
that impairments in glucose regulation caused by variants
at the HNF1B and CDKN2A/B loci may be attenuated by
physical activity. In the event that these interactions are
independently replicated, they may shed light of the mech-
anisms through which physical inactivity and genetic
variants inﬂuence the risk of type 2 diabetes; whether this
information will prove useful for the targeted prevention
of type 2 diabetes remains to be determined.
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